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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S3761.7 mg/kg body weight/day); OVX with 17b-estradiol (E2, 0.17 mg/kg
body weight/day); and OVX with BHH10 in graded doses (250, 500, or
750 mg/kg/day). Daily oral administration of BHH10, ALN or E2 started
on week 2 after OVX and continued for 12 weeks. Body and uterus
weight, serum biochemical bone turnover markers, bone mineral
density (BMD), and microarchitectural parameters were assessed.
Results: BHH10 inhibited OVX-induced body weight gain, uterus atro-
phy, and signiﬁcantly decreased levels of the bone formation markers
serum alkaline phosphatase (ALP) and osteocalcin (OCN), and the bone
resorption parameter C-telopeptide type 1 collagen (CTX). BHH10 also
notably enhanced BMD and bone microstructure in both total femur
and femoral neck measurements compared to OVX rats.
Conclusions: These results suggested that BHH10 administration
improved biochemical markers of bone metabolism, bone bio-
mechanical quality, and bone structural integrity in OVX rats. The
potent anti-osteoporosis effect of BHH10 might be mediated by its
action of stimulating bone formation and regulating bone resorption
with no signiﬁcant toxicity.
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LOW DOSAGE OF MONOIODOACETIC ACID INDUCES ARTHRITIS
WITHOUT BONE DEFECT IN A RAT MODEL
M. Udo y, I. Sekiya z, K. Tsuji x, N. Ozeki y, Y. Nakagawa y, T. Ohara y,
R. Saito y, K. Yanagisawa y, T. Muneta y. yDept. of Joint Surgery and Sports
Med., Tokyo Med. and Dental Univ., Tokyo, Japan; zCtr. for Stem Cell and
Regenerative Med., Tokyo Med. and Dental Univ., Tokyo, Japan; xDept. of
Cartilage Regeneration, Tokyo Med. and Dental Univ., Tokyo, Japan
Purpose: An arthritis model by monoiodoacetic acid is usually used to
evaluate pain in rodents. The dose of MIA commonly used for the model
is too high and often results in not only cartilage degeneration but also
bone destruction within a short period, unsuitable for morphological
observation as an osteoarthritis model. The ﬁrst purpose of the study
was to examine the dose effect of MIA on cartilage and bone damage
sequentially for the establishment of a rat arthritis model similar to
osteoarthritis.
Materials and methods: Male Wistar rats at 8 weeks old received a
single intra-articular injection of MIA in the right knee and PBS in the
left knee. The dose of MIA was 0.1, 0.2, 0.5, and 1 mg/50 ml (n ¼ 4).
Articular cartilage was evaluated macroscopically and histologically at
2, 4, 6, 8 and 12 weeks.
Results: In the 0.1 mg and 0.2 mg groups, cartilage matrix already was
decreased at 2 week, and the cartilage was destroyed thereafter. Sub-
chondral bone was focally exposed at 8 weeks in the 0.1 mg group and
at 4 weeks in the 0.2 mg group. Bone destructionwas not observed until
12 weeks in the 0.1 mg group, while it appeared at 12 weeks in the 0.2
mg group. In the 0.5 mg group, cartilage destruction appeared at 2
week, and bone destruction appeared at 4 weeks. In the 1 mg group,
cartilage disappeared and bone was severely destroyed at 2 weeks.
Conclusion: Reports can often be seen of a rat arthritis model in which
higher than 1 mg MIA was used which was too high, resulting in rapid
bone destruction. 0.1 and 0.2 mg MIA induced early arthritis showing
cartilage inﬂammation without severe bone damage. The dose of MIA
and duration after the injection were important factors affecting
severity of arthritis. Our data obtained here provide useful information
for establishment of a rat arthritis model to accomplish a particular
objective.Osteoarthritis Clinical Aspects
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IMPACT OF COMPONENTS OF THE METABOLIC SYNDROME ON KNEE
OSTEOARTHRITIS PROGRESSION IN THE SEKOIA STUDY
F. Eymard y, M. Edwards z, C. Parsons z, C. Cooper z, F. Petit-dop x,
J-Y. Reginster k, O. Bruyere k, P. Richette{, X. Chevalier y. yAP-HP Henri
Mondor Hosp., Creteil, France; z Southampton Gen. Hosp., Southampton,
United Kingdom; x Servier clinical Dept., Suresnes, France; kUniv. of
Liege, Liege, Belgium; {AP-HP Lariboisiere Hosp., Paris, France
Purpose: Recent studies have suggested that components of the met-
abolic syndrome might be involved in the pathophysiology of osteo-
arthritis (OA). However, their impact on joint space narrowing in
patients with established OA is unknown.We investigated the impact of
each component of the metabolic syndrome on knee joint space
narrowing.Methods: 559 men and women aged over 50 years with symptomatic
knee OA (K&L 2–3) were recruited to the placebo arm of the SEKOIA
study (98 centres; 18 countries). The presence or absence of type 2
diabetes, hypertension, and hyperlipidaemia was determined at base-
line interview. Height and weight were measured and BMI calculated.
Minimal tibiofemoral joint space on plain radiographs of the knee was
assessed by two independent readers at baseline and then yearly for up
to 3 years.
Results: The mean (SD) age of participants was 62.8 (7.5) years. A total
of 43.8% had a BMI>30, 6.6% had type 2 diabetes, 45.1% hypertension
and 27.6% hyperlipidaemia. Those with type 2 diabetes had signiﬁcantly
faster rates of joint space loss over the duration of the study than those
without (0.26 and 0.14 mm/year respectively; p ¼ 0.01). This relation-
ship also held true for an annualised assessment of joint space nar-
rowing. No evidence of an association was found between the
remaining components of the metabolic syndrome (obesity, hyper-
tension and hyperlipidaemia) and the rate joint space narrowing. The
relationship between type 2 diabetes and both annual and 3-year joint
space loss remained statistically signiﬁcant after adjustment for BMI (p
¼ 0.011 and p ¼0.027 respectively). When sexes were examined sepa-
rately, type 2 diabetes was a signiﬁcant predictor of joint space loss in
men but not women.
Conclusions: Type 2 diabetes was a predictor of the rate of joint space
narrowing in individuals with established knee OA. No such relation-
ships were found for obesity, hypertension, and hyperlipidaemia. Fur-
ther studies are required to replicate these ﬁndings and to explore a
biological explanation.
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SAFETY AND EFFICACY OF FX006 IN PATIENTS WITH
OSTEOARTHRITIS OF THE KNEE
N. Bodick y, J. Lufkin y, C. Willwerth y, A. Kumar y, J. Bolognese z,
C. Schoonmaker z, D. Hunter x, M.D. Clayman y. y Flexion Therapeutics,
Burlington, MA, United States; zCytel, Inc., Cambridge, MA, United
States; xRoyal North Shore Hosp., St. Leonards, NSW, Australia
Purpose: FX006 is a novel sustained-release formulation of tri-
amcinolone acetonide (TCA) in poly(lactic-co-glycolic) acid micro-
spheres intended to maintain prolonged therapeutic concentrations of
TCA in the joint following intra-articular (IA) injection. In a previous
clinical study, FX006 has demonstrated both prolonged residency in the
joint and reduced plasma concentrations relative to an equivalent dose
of an approved immediate release suspension of TCA (TCA IR). The
initial study of the safety and efﬁcacy of FX006 relative to the approved
dose of TCA IR in patients with OA of the knee is reported here.
Methods: In this Phase 2 study, patients with Baseline weekly mean of
the average daily pain intensity (ADP) of5 –9 on an 11 point Numeric
Rating Scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can
imagine) were randomized (1:1:1:1) and treated with a single IA injec-
tion of FX006 (containing 10, 40 or 60 mg of TCA) or 40 mg of TCA IR.
Over the ensuing 12 weeks, ADP was collected each day using an auto-
mated reporting system. The primary endpoint was the change from
Baseline in theweekly mean of ADP atWeeks 8,10 and 12. Key secondary
endpoints included WOMAC (pain, stiffness and function), responder
status, and patient and clinician global impression of change.
Results: 228 patients were randomized and treated (FX006 10 mg, n ¼
58; FX006 40 mg, n ¼ 59; FX006 60 mg, n ¼ 60; TCA IR, n ¼ 51).
Treatment arms were well balanced with respect to demographics (age,
61.5 yrs  9.33; BMI, 30.5  4.75; female, 52.6%) and baseline charac-
teristics (weekly mean of ADP at Baseline: 6.5; KL grade 3 64%). A dose
dependent improvement in the weekly mean of ADP relative to TCA IR
was evident up to 40 mg. The 10 mg dose produced effects that were
improved relative to TCA IR at Weeks 2 through 12 and approached
signiﬁcance at Weeks 6, 7, and 8. The 40 mg dose produced effects that
were improved at Weeks 2 through 12 and superior to TCA IR at Weeks
5–0 (2-sided, p < 0.05) with an average pain reduction relative to TCA IR
of 0.9 (Figure 1). The 60 mg dose did not provide additional improve-
ment relative to the 40 mg dose. Maximal effect in the weekly mean of
the ADPwas achieved atWeeks 7 and 8. Key secondary endpoints for the
40 mg dose at the 8-week endpoint were also signiﬁcant (2-sided, p <
0.05) (see Table 1). Eighty–ﬁve to 93% of patients at the 40 mg dose
achieved a least a 20% response (Figure 2) at Weeks 2 through 12 ach-
ieving signiﬁcance relative to TCA IR atWeeks 5 (p¼ 0.031), 8 (p¼ 0.041)
and 12 (p ¼ 0.030). There were no related SAEs. AEs were generally mild
and unrelated to study drug. Local knee-related AEs, lab assessments,
